376 related articles for article (PubMed ID: 16158069)
21. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
22. Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.
Gotta V; Cools F; van Ammel K; Gallacher DJ; Visser SA; Sannajust F; Morissette P; Danhof M; van der Graaf PH
Br J Pharmacol; 2015 Sep; 172(17):4364-79. PubMed ID: 26076100
[TBL] [Abstract][Full Text] [Related]
23. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
24. Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin.
Couderc JP; McNitt S; Hyrien O; Vaglio M; Xia X; Polonsky S; Moss AJ; Zareba W
Drug Saf; 2008; 31(3):249-60. PubMed ID: 18302449
[TBL] [Abstract][Full Text] [Related]
25. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
[TBL] [Abstract][Full Text] [Related]
27. Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.
Grosjean P; Urien S
J Clin Pharmacol; 2012 Mar; 52(3):329-38. PubMed ID: 21415283
[TBL] [Abstract][Full Text] [Related]
28. Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium.
Holzgrefe H; Ferber G; Champeroux P; Gill M; Honda M; Greiter-Wilke A; Baird T; Meyer O; Saulnier M
J Pharmacol Toxicol Methods; 2014; 69(1):61-101. PubMed ID: 23689033
[TBL] [Abstract][Full Text] [Related]
29. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
Lu HR; Gallacher DJ; Yan GX
J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
[TBL] [Abstract][Full Text] [Related]
30. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
31. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
[TBL] [Abstract][Full Text] [Related]
32. Effects of moxifloxacin on QT interval in conscious dogs.
Mittelstadt SW; Hart SM
J Vet Pharmacol Ther; 2005 Jun; 28(3):253-6. PubMed ID: 15953198
[TBL] [Abstract][Full Text] [Related]
33. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
34. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
[TBL] [Abstract][Full Text] [Related]
35. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Chiba K; Sugiyama A; Hagiwara T; Takahashi S; Takasuna K; Hashimoto K
Eur J Pharmacol; 2004 Feb; 486(2):189-200. PubMed ID: 14975708
[TBL] [Abstract][Full Text] [Related]
36. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
37. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.
Altin T; Ozcan O; Turhan S; Ongun Ozdemir A; Akyurek O; Karaoguz R; Guldal M
Can J Cardiol; 2007 Sep; 23(11):907-8. PubMed ID: 17876386
[TBL] [Abstract][Full Text] [Related]
38. T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition.
Couderc JP; Xia X; Peterson DR; McNitt S; Zhao H; Polonsky S; Moss AJ; Zareba W
Heart Rhythm; 2011 Jul; 8(7):1036-43. PubMed ID: 21315844
[TBL] [Abstract][Full Text] [Related]
39. Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.
Chain AS; Dubois VF; Danhof M; Sturkenboom MC; Della Pasqua O;
Br J Clin Pharmacol; 2013 Nov; 76(5):708-24. PubMed ID: 23351036
[TBL] [Abstract][Full Text] [Related]
40. Statistical characteristics of moxifloxacin-induced QTc effect.
Yan LK; Zhang J; Ng MJ; Dang Q
J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
